Patents Assigned to Pfizer
  • Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
    Publication number: 20070191386
    Abstract: Bicyclo-pyrazole compounds of formula (I), as herein defined, are useful for treating diseases linked to disregulated protein kinases.
    Type: Application
    Filed: April 10, 2007
    Publication date: August 16, 2007
    Applicant: Pfizer Italia S.r.l.
    Inventors: Daniele Fancelli, Valeria Pittala, Mario Varasi
  • PPAR ACTIVATORS
    Publication number: 20070191429
    Abstract: PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
    Type: Application
    Filed: March 30, 2007
    Publication date: August 16, 2007
    Applicant: PFIZER INC.
    Inventors: Scott Bagley, Thomas Brandt, Robert Dugger, William Hada, Cheryl Hayward, Zhengyu Liu
  • Combination therapy for osteoporosis
    Patent number: 7255984
    Abstract: Pharmaceutical combination compositions including certain estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compositions are useful for the treatment of bone disorders including osteoporosis.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: August 14, 2007
    Assignee: Pfizer Inc.
    Inventors: Hua Zhu Ke, David D. Thompson
  • Fluorine NMR spectroscopy for biochemical screening
    Patent number: 7255985
    Abstract: High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498–505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF3 (or CF) moiety on the substrate and utilizes 19F NMR spectroscopy for the detection of the starting and enzymatically modified substrates. Experiments can be performed in real time or in an endpoint assay format using protein and substrate concentrations comparable to the ones used by other HTS techniques. Application of this technique to the phosphorylation of a substrate by the protein Ser/Thr kinase AKT1 is presented.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: August 14, 2007
    Assignee: Pfizer Italia S.r.l.
    Inventors: Claudio Dalvit, Elena Ardini, Maria Magdalena Flocco, Gianpaolo Fogliatto, Nicola Mongelli, Marina Veronesi
  • Compounds for the treatment of neurodegenerative disorders
    Patent number: 7253195
    Abstract: The present invention relates to compounds of the Formula wherein R3, R5, R7, U, X, Y and Z are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: August 7, 2007
    Assignee: Pfizer Inc
    Inventor: Yuhpyng L. Chen
  • (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity
    Patent number: 7253211
    Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: August 7, 2007
    Assignee: Pfizer Inc.
    Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
  • Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
    Patent number: 7250407
    Abstract: The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc.
    Inventors: Jean-Louis Dasseux, Renate Sekul, Klaus Büttner, Isabelle Cornut, Günther Metz, Jean Dufourcq
  • Method of treatment of transplant rejection
    Patent number: 7250420
    Abstract: A method of treating or preventing chronic organ transplant rejection comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc.
    Inventor: Paul S. Changelian
  • Pyrrole-based HMG-CoA reductase inhibitors
    Patent number: 7250444
    Abstract: HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc.
    Inventors: Robert Michael Kennedy, William Keun-Chan Park, Bruce David Roth, Yuntao Song, Bharat K. Trivedi
  • Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
    Patent number: 7250518
    Abstract: Compounds of the formula: useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc.
    Inventors: Thomas V. Magee, Anthony Marfat, Robert J. Chambers
  • Compounds as CRFreceptor antagonists
    Patent number: 7250418
    Abstract: The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF1 receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF1 receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF1 receptors.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc
    Inventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest
  • Methods for preventing cattle reproductive diseases
    Publication number: 20070172877
    Abstract: The present invention relates to methods for treating or preventing diseases or disorders in a pregnant cow and calf nursing a pregnant cow caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PIV3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a safe modified live viral combination vaccine further combined with a multivalent bacterin vaccine.
    Type: Application
    Filed: March 15, 2007
    Publication date: July 26, 2007
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Michael Ellsworth, Martin Ficken, Brian Fergen, Cassius Tucker
  • Cannabinoid receptor ligands and uses thereof
    Patent number: 7247628
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment diseases, conditions and/or disorders herein.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: July 24, 2007
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: Robert L. Dow, Marlys Hammond
  • SUBSTITUTED IMIDAZOLES
    Publication number: 20070167506
    Abstract: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    Type: Application
    Filed: January 4, 2007
    Publication date: July 19, 2007
    Applicant: PFIZER INC.
    Inventors: NATHAN ANTHONY LOGAN CHUBB, MARK ROGER COX, JEROME SEBASTIEN DAUVERGNE, RICHARD ANDREW EWIN, CHRISTELLE LAURET
  • Sulfonamide derivatives for the treatment of diseases
    Patent number: 7244766
    Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: January 19, 2005
    Date of Patent: July 17, 2007
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Mark Edward Bunnage, Paul Alan Glossop, Kim James, Charlotte Alice Louise Lane, Russel Andrew Lewthwaite, Ian Brian Moses, David Anthony Price, Nicholas Murray Thomson
  • Pyrazole-amine compounds for the treatment of neurodegenerative disorders
    Patent number: 7244757
    Abstract: The present invention relates to compounds of the Formula wherein R1, R3, R4, R5, R6, R7 and R8 are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: July 17, 2007
    Assignee: Pfizer Inc
    Inventors: Yuhpyng L. Chen, Lei Zhang
  • ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES
    Publication number: 20070161681
    Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein the substituents are as defined in the specification.
    Type: Application
    Filed: January 30, 2007
    Publication date: July 12, 2007
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Anthony Marfat, Robert Chambers, Thomas Magee
  • Formamide derivatives for the treatment of diseases
    Patent number: 7241810
    Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: March 21, 2005
    Date of Patent: July 10, 2007
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Mark Edward Bunnage, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite, Paul Alan Glossop, Kim James, David Anthony Price
  • 3-azabicyclo[3.2.1]octane derivatives
    Patent number: 7241887
    Abstract: The subject invention relates to 3-azabicyclo[3.2.1]octane derivatives, pharmaceutical compositions comprising such derivatives and methods of using such derivatives to treat disease states, disorders and conditions mediated by opioid receptors. The subject invention also particularly relates to using such derivatives to treat certain disorders and conditions, for example irritable bowel syndrome, drug addiction, depression, anxiety, schizophrenia and eating disorders, among others.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: July 10, 2007
    Assignee: Pfizer Inc
    Inventors: Jotham W. Coe, Stanton McHardy, Crystal G. Bashore
  • NK1 antagonists
    Patent number: 7241798
    Abstract: The invention is to compounds exhibiting neurokinin inhibitory properties, pharmaceutical compositions comprising same and methods of treatment for neurokinin-mediated conditions.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: July 10, 2007
    Assignee: Pfizer Inc.
    Inventors: Barbara E. Segelstein, Travis T. Wager, Willard M. Welch